JCI Insight
US$ 22.66
semaglutide soul Oral Reduces CV Events in T2DM β Trial (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π Pharmacy - At ADA 2025,
Description
K., Liu B., Cui X., Brown K
However, realizing this promise will require careful execution: ensuring regulatory readiness, maintaining data integrity, and measuring actual patient outcome gains
The drugs follow a slow escalation schedule, and patients who stop early, whether due to side effects or cost, are likely leaving before the medication has reached its full effect
It must be prescribed by a licensed provider following a medical consultation
NAFLD sounding the alarm on a silent epidemic
